Population pharmacokinetic analysis of a long-acting recombinant factor IX-FC fusion protein (RFIXFC) in patients with severe haemophilia B

被引：0
|
作者：
Diao, L. [1 ]
Li, S. [2 ]
Nestorov, I. [3 ]
Jiang, H. [2 ]
机构：
[1] Biogen Idec Hemophilia, Waltham, MA USA
[2] Biogen Idec Hemophilia, Preclin & Clin Res, Waltham, MA USA
[3] Biogen Idec Inc, Pharmacometr, Cambridge, MA USA
来源：
HAEMOPHILIA | 2013年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [21] Recombinant Fusion Factor VIII-Fc Fusion Protein in Severe Haemophilia A Patients
    Le Quellec, Sandra
    HEMATOLOGIE, 2014, 20 (06): : 304 - 306
  • [22] Perioperative Management Of Subjects With Haemophilia A In The ASPIRE Study With Long-acting Recombinant Factor VIII FC Fusion Protein (rFVIIIFc)
    Mahlangu, J.
    Ragni, M.
    Gupta, N.
    Rangarajan, S.
    Nogami, K.
    Li, X.
    Allen, G.
    Pierce, G. F.
    Robinson, B.
    HAEMOPHILIA, 2015, 21 : 82 - 82
  • [23] Long-term efficacy and safety of prophylactic treatment with recombinant factor IX FC fusion protein (rFIXFc) in subjects with severe or moderate haemophilia B: final longitudinal analysis of B-LONG/kids B-LONG and B-YOND
    Shapiro, A. D.
    Kulkarni, R.
    Ragni, M. V.
    Mahlangu, J.
    Oldenburg, J.
    Nolan, B.
    Ozelo, M. C.
    Willemze, A.
    Feng, J.
    Barnowski, C.
    Barnes, C.
    HAEMOPHILIA, 2019, 25 : 39 - 40
  • [24] Individualised Prophylaxis In Children With Haemophilia B Treated Long Term With Recombinant Factor Ix Fc Fusion Protein (RFIXFC): Updated Interim Results Of The B-YOND Extension Study
    Fischer, K.
    Kulkarni, R.
    Nolan, B.
    Bennett, C. M.
    Perry, D. J.
    Barnes, C.
    Yuan, H.
    Ramirez-Santiago, A.
    Ferrante, F.
    Dumont, J.
    Lethagen, S.
    Barnowski, C.
    HAEMOPHILIA, 2017, 23 : 94 - 94
  • [25] Long-Term Safety and Efficacy of Recombinant Factor Ix Fc (rFIXFc) for Treatment of Severe Haemophilia B: European Subgroup Interim Analysis of the B-YOND Study
    Chambost, H.
    Perry, D.
    Holmstrom, M.
    Hermans, C.
    Ferrante, F.
    Szamosi, J.
    Lethagen, S.
    HAEMOPHILIA, 2017, 23 : 69 - 70
  • [26] Clinical Outcomes in Children with Haemophilia B Treated Long Term with Recombinant Factor IX FC Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-YOND Extension Study
    Fischer, K.
    Kulkarni, R.
    Nolan, B.
    Bennett, C. M.
    Perry, D. J.
    Barnes, C.
    Yuan, H.
    Ramirez-Santiago, A.
    Pierce, G. F.
    Mei, B.
    HAEMOPHILIA, 2016, 22 : 47 - 48
  • [27] Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B
    Suzuki, A.
    Tomono, Y.
    Korth-Bradley, J. M.
    HAEMOPHILIA, 2016, 22 (05) : E359 - E366
  • [28] Safety, efficacy and pharmacokinetics of recombinant factor IX FC fusion protein in children with haemophilia B (KIDS B-LONG)
    Fischer, K.
    Kulkarni, R.
    Nolan, B.
    Mahlangu, J.
    Rangarajan, S.
    Gambino, G.
    Diao, L.
    Cristiano, L. M.
    Pierce, G. F.
    Allen, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 87 - 87
  • [29] Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B
    Wang, C.
    Young, G.
    HAEMOPHILIA, 2018, 24 (03) : 414 - 419
  • [30] Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX
    Escobar, M. A.
    Tehranchi, R.
    Karim, F. A.
    Caliskan, U.
    Chowdary, P.
    Colberg, T.
    Giangrande, P.
    Giermasz, A.
    Mancuso, M. E.
    Serban, M.
    Tsay, W.
    Mahlangu, J. N.
    HAEMOPHILIA, 2017, 23 (01) : 67 - 76
12345